Wenbo Ding

Wenbo Ding

Auto-generated profile, based on publicly available information

Wenbo Ding

Cardio-Metabolic Medicine Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Cardiorenal Medicine
Verified
Journal Article
Open access
LLLubi Lei
Lubi Lei
JLJingkuo Li
Jingkuo Li
WDWenbo Ding
Wenbo Ding
WWWei Wang
Wei Wang
YYYanwu Yu
Yanwu Yu
YGYuanlin Guo
Yuanlin Guo
Background: The American Heart Association has recently updated the Cardiovascular-Kidney-Metabolic (CKM) Health Advisory, proposing a new framework for defining, staging, and predicting CKM risk. However, the prevalence and adverse effects of the CKM stages remain insufficiently characterized. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) (1999–2018), including 18,350 US adults aged 20–79 years. CKM syndrome encompasses subclinical or clinical cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic risk factors. The participants were categorized into 4 CKM stages based on their clinical severity. We assessed associations of CKM stages with mortality risk and life expectancy. Results: Only 12.9% of participants were classified as having CKM stage 0. The prevalence of CKM stages 1, 2, 3, and 4 was 23.1%, 53.6%, 3.6%, and 6.7%, respectively. Compared with CKM stage 0, individuals in stage 4 had a markedly higher risk of all-cause mortality (HR: 4.30, 95% CI: 2.95–6.26) and lost 15.5 (12.5–19.8) years of life at age 50 years. Sex and racial/ethnic disparities were also observed. Conclusions: A higher CKM stage was strongly associated with increased mortality and reduced life expectancy. Our findings underscore the urgent need for enhanced CKM health management, social support, and policy intervention.

1 August 2026 in Current Traditional Medicine
Verified
Journal Article
Open access
PDF file
WDWenbo Ding
Wenbo Ding
YGYing Gao
Ying Gao
RXRuixia Xu
Ruixia Xu
LZLihua Zhang
Lihua Zhang
JLJing Li
Jing Li
YGYuan-Lin Guo
Yuan-Lin Guo
Introduction: This meta-analysis aimed to evaluate the efficacy of berberine in reducing Liver Lipid Content (LLC) and its safety in patients with Non-alcoholic Fatty Liver Disease (NAFLD). Method: A systematic literature search was conducted in databases including PubMed and the Cochrane Library up to September 2023. The primary efficacy endpoint was the change in LLC assessed by ultrasonography. Secondary endpoints included biochemical indicators and BMI. Safety endpoints were gastrointestinal reactions. Results: A total of 15 randomized controlled trials involving 1472 patients (727 in the berberine group and 745 in the control group) were included. Comparing the overall number of effective patients in the berberine group with the control group, it was found that berberine can reduce the LLC more obviously (OR=3.14; 95% CI [2.04, 4.82]; p<0.01). Berberine also significantly improved hepatic enzymes, blood lipids, plasms glucose levels, and reduced BMI. Pooled safety analysis showed that berberine was associated with a higher incidence of minor gastrointestinal reactions, such as vomiting and abdominal pain (OR=1.85; 95%CI [1.23, 2.77]; p<0.01). Discussion: The efficacy of berberine in reducing LLC is consistent with findings from previous animal and clinical studies. Its beneficial effects are mediated through multiple mechanisms. Furthermore, clinical trials have established that berberine does not cause serious adverse events. Conclusion: Berberine was associated with a significant reduction in LLC in patients with NAFLD, with a generally acceptable safety profile of minor gastrointestinal reactions.